SCHEDULE 14A INFORMATION
Proxy Statement Pursuant To Section 14(a) Of
The Securities Exchange Act Of 1934
Filed by the Registrant [X]
Filed by a Party other than the Registrant [_]
Check the appropriate box:
[_] Preliminary Proxy Statement
[_] CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTED BY
RULE 14A-6(E)(2))
[_] Definitive Proxy Statement
[X] Definitive Additional Materials
[_] Soliciting Material Pursuant to Section 240.14a-12
ICN Pharmaceuticals, Inc.
--------------------------------------------------------
(Name of Registrant as Specified in its Charter)
N/A
--------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[_] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
-------------------------------------------------------------------
(2) Aggregate number of securities to which transaction applies:
-------------------------------------------------------------------
(4) Proposed maximum aggregate value of transaction:
-------------------------------------------------------------------
(5) Total fee paid:
-------------------------------------------------------------------
[_] Fee paid previously with preliminary materials.
[_] Check box if any part of the fee is offset as provided by Exchange Act
Rule 0-11(a)(2) and identify the filing for which the offsetting fee was
paid previously. Identify the previous filing by registration statement
number, or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
-------------------------------------------------------------------
(2) Form, Schedule or Registration Statement No.:
-------------------------------------------------------------------
(3) Filing Party:
-------------------------------------------------------------------
(4) Date Filed:
-------------------------------------------------------------------
Following is the text of materials ICN used in presentations to
stockholders on May 22, 2001. The Medical Economics article was reproduced
with the consent of the editor for use as proxy soliciting materials.
Copyright (C) 2001 by Medical Economics Company.
Reproduced by permission from Medical Economics magazine.
Website: www.memag.com
MEDICAL ECONOMICS
THE BUSINESS MAGAZINE OF THE MEDICAL PROFESSION (COPYRIGHT) APRIL 9, 2001
25 top health care stocks
will they lead the next market boom?
[PICTURE OMITTED - SECTION OF DNA DOUBLE HELIX]
Keep your practice alive when the computer goes dead
-----------------------
Your nest egg just got bigger
-----------------------
Was I doing my duty-or ratting on a colleague?
BEST HEALTH CARE STOCKS
52-WEEK RECENT P-E
TICKER HIGH-LOW PRICE RATIO
------ -------- ----- -----
Accredo Health ACDO 37-12 26 48
Amgen AMGN 80-50 65 62
Applied Biosystems ABI 133-143 50 50
Aradigm ARDM 39-6 6 N/A
ArQule ARQL 35-6 14 57
Biomet BMET 42-18 40 40
CardioDynamics
International CDIC 13-2 3 N/A
Chiron CHIR 59-33 44 N/A
Cigna CI 137-61 111 18
Cor Therapeutics CORR 67-22 28 N/A
Eli Lilly LLY 109-57 78 28
Genentech DNA 100-42 46 N/A
Genzyme (General
Division) GENZ 104-40 86 69
Human Genome Sciences HGSI 107-25 48 N/A
ICN Pharmaceuticals ICN 42-21 24 N/A
Icos ICOS 60-27 46 N/A
ImClone Systems IMCL 69-26 30 N/A
Johnson & Johnson JNJ 106-69 94 28
Medtronic MDT 62-45 47 46
Merck MRK 97-55 73 25
Myriad Genetics MYGN 138-19 43 N/A
Pfizer PFE 49-33 40 43
Pharmacia PHA 64-39 49 76
St. Jude Medical STJ 65-24 51 34
Waters WAT 91-37 51 44
All data as of March 31, 2001. Stocks with four-letter tickers trade on
Nasdaq. All others trade on New York Stock Exchange. N/A: Not Available,
because the company has no earnings or its P-E ratio is too high to be
meaningful.
Source: Dow Jones
ICN PHARMACEUTICALS makes and sells nutritional and pharmaceutical
products that treat viral and bacterial infections, skin diseases,
neuromuscular disorders, cancer, heart disease, diabetes, and psychiatric
disorders. Its leading anti-viral agent, Virazole, is approved in 43
countries to combat diseases including flu, herpes, and HIV.
Royalties for Rebetron, an anti-viral drug used to treat hepatitis
patients, were expected to reach $160 million last year. An estimated 2
percent of the world's population is infected with hepatitis C.
The company is introducing a more efficient version of the drug, and
it plans to start selling Rebetron in Japan.
ABOUT THESE COMPANIES
Segment An expert says...
------- -----------------
HUMAN GENOME SCIENCES Biotechnology "This stock is for
the risk-tolerant;
it has high upside
potential."
(Mireskandari)
ICN PHARMACEUTICALS Pharmaceuticals "Look for strong
gains from this
excellent company."
(Yellen)
ICOS Pharmaceuticals "Could be a real
winner in both the
short and the long
term."
(McCamant)
IMCLONE SYSTEMS Pharmaceuticals "Excellent
management and
advanced science
could make share
price soar, and it's
a good buy right
now."
(McCamant)
JOHNSON & JOHNSON Pharmaceuticals "Won't grow 30
percent a year like
the small, new
companies, but I can
see 12 to 14 percent
annual returns."
(Duarte)
MEDTRONIC Medical supplies "Almost a can't miss;
a great company that
can bring top
returns."
(Duarte)
MERCK Pharmaceuticals "A good stock to buy
at any time."
(Duarte)
MYRIAD GENETICS Biotechnology "Stands a good
chance of 25 percent
annualized returns,
but could be risky."
(Mireskandari)
PFIZER Pharmaceuticals "Stock price has
more than doubled in
the past five years
[accounting for
splits], and should
do very well in the
coming decade."
(Mireskandari)
PHARMACIA Pharmaceuticals "Share price could
increase in the
range of 15 percent
annualized in the
next decade."
(Mireskandari)
ST. JUDE MEDICAL Medical Supplies "It has a great deal
of growth potential,
and is one of the
most underrated
companies in medical
equipment."
(Duarte)
WATERS Medical Supplies "If you can buy on a
dip, this growth
stock could double
in price within a
couple of years."
(Borzilleri)
[LOGO - NLITE(TM) LASER COLLAGEN REPLENISHMENT]
FOR PERIOCULAR WRINKLE REDUCTION
WE ARE PLEASED TO PROVIDE THE NLITE LCR LASER, AS CLEARED BY THE FDA,
FOR NON-ABLATIVE PERIOCULAR WRINKLE REDUCTION.
Another anti-aging solution from ICN Pharmaceuticals, Inc.
[PHOTO OMITTED - BEFORE]
[PHOTO OMITTED - SINGLE TREATMENT]
LASER TYPE: Pulsed Dye Laser
WAVELENGTH: 585 nm
PULSE CHARACTERISTICS:
Pulse Duration: 350 us
Spot Size: 5 mm
Repetition Rate: 2 hz, Software Controlled
BEAM DELIVERY:
Lens-Coupled Flexible Optical Fiber
with Handpiece
AIMING BEAM:
Laser Type: 0.8 mW Diode Laser, Class II
Wavelength: 670 nm (red)
MODE STRUCTURE: Top Hat, +2% of Mean
SMARTRIDGEDYE LIFE: 50,000 Pulses
LASER COOLING METHOD:
Self Contained De-ionized Water Cooled
Integral Chiller
SIZE: 24" x 36" x 41"
ELECTRICAL REQUIREMENTS:
220-240 VAC, 25A 50/60 Hz, Single Phase
USER INTERFACE:
Colar LCD withTouch Screen Interface
ENVIRONMENTAL REQUIREMENTS:
10 degrees C to 30 degrees C Non-Condensing Humidities
below 75% RH.
SAFETY: Class IV Laser
The NLite LCR(TM) Laser triggers collagen replenishment without general
tissue stimulation or irritation.
Clinical studies of the NLite LCR(TM) Laser indicate collagen growth with
shorter treatment cycles than existing technologies.
Clinical studies report 84% comparable results to CO2 laser therapy for
periocular wrinkle reduction with no downtime.
Post treatment reports indicate virtually no side effects, no
hypopigmentation or hyperpigmentation.
Does not require the use of a surface cooling device.
[PICTURE OMITTED - NLite LCR (TM) Laser]
For more information, please contact:
800-256-3399
www.NLiteLCR.com
[LOGO - ICN / ICN MEDICAL ALLIANCE, INC.]
[LOGO - DANGER]
ICN Pharmaceuticals, Inc. 2001
In addition to providing the NLite LCR(TM) System for
periocular wrinkle reduction, ICN Medical Alliance is proud
to offer you the following aesthetic lasers on a daily-access basis:
-----------------------------------------------------------
FULL OFFERING OF PREMIER LASERS WITH TECHNICAL SUPPORT:
Ultra Pulse CO2
Erbium:YAG
Aura KTP/532 with Cooler
Alexandrite
Flashlamp Pulsed Dye
Q-Switched Frequency Doubled ND:YAG
Apogee 6200 Alexandrite
-----------------------------------------------------------
-----------------------------------------------------------
PATIENT INDICATIONS:
Facial Wrinkles
Pigmented Lesions
Birthmarks
Facial and Body Hair
Acne Scars
Tattoos
Puffy Eyelids
Facial and Leg Veins
Vascular Lesions
-----------------------------------------------------------
-----------------------------------------------------------
ICN PHARMACEUTICAL SKINCARE PRODUCTS:
Glyquin - 4% Hydroquinone with 10% glycolic acid
Kinerase - Topical anti-aging lotion or cream with N6-furfuryladenine
Glyderm - Esterified glycolic acid line of peels, cleansers,
and moisturizers
-----------------------------------------------------------
WHY CHOOSE ICN MEDICAL ALLIANCE?
1. The Only National Office-Based Aesthetic Surgical Services Company
2. Convenient Scheduling
3. Extensive Insurance Coverage
4. State-of-the-Art Technology
5. Unmatched Experience
6. Commitment to Quality
7. Trained Technicians
8. Physician Education Programs
9. Office Staff Education
10. Patient Education
11. Aesthetic Surgery Network
12. Practice Building and Marketing Support
13. The only company to provide a total skincare solution
Also available: The Rejuvasilk(TM) Microdermabrasion System.
Call for a free demo!
800-256-3399
www.NLiteLCR.com